Ultragenyx Pharmaceutical | RARE - Operating Expenses



Ultragenyx Pharmaceutical reported $274.38M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Agios Pharmaceuticals USD 139.51M 24.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Insmed USD 361.29M 20.33M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Kyowa Hakko Kirin JPY 113.11B 15.82B Jun/2025
MacroGenics USD 59M 23.06M Jun/2025
Moderna USD 1.04B 113M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025